Content: On the morning of February 9, Mr. Jia Di, Deputy Secretary of the Party Committee and Mayor of Dongli District, Tianjin, and other comrades from District Government Office, Talent Office, Industry and Information Bureau, Science and Technology Bureau visited Laviana Pharma (Tianjin) Co., Ltd. (hereinafter referred to as "Tianjin Laviana") to see the production and operation situation of the enterprise and help to solve operation problems.

Mr. Chen Wenting, Chairman of the Board, accompanied Mr. Jia Di and other leaders to visit the R&D building of Tianjin Laviana, and reported on the milestones, the current situation, and the positioning of Tianjin Laviana and its CDMO platform service capability. Founded in 2005, Laviana Pharma has always been a high-tech contract development manufacture organization (CDMO) specilize in innovative pharmaceutical industrialization outsourcing services. Guided by the culture of "in pursuit of humanity, scientificity, customer satisfaction, and excellence", Laviana Pharma will strive to build the world's leading innovative process research and production outsourcing service platform.

Mr. Jia Di visited the NMR lab, R&D lab, GMP kilo-level lab and analytical lab, and asked about the operation of several equipments in detail. Mr. Jia Di said that the equipment is the foundation and guarantee for R&D and production enterprises seeking sustainable development. In addition, Mr. Jia also showed great concern about the development of Laviana Pharma, and expressed that he would communicate in detail to understand the difficulties encountered by Laviana and help to solve problems and grow the business in the long run by leveraging supportive policies.

Chairman Chen Wenting introduced that since its establishment, Tianjin Laviana has always attached importance to independent R&D and independent intellectual property rights. By filing technology contracts, Laviana turns patent achievements into comprehensive service capabilities, and provides customers with efficient, innovative drugs and services. Such efforts also served the growth of Tianjin Laviana's income, contributed a compound growth rate of more than 20% in the past three years. To upgrade its comprehensive service capacity, Tianjin Laviana will finish the third phase within 2022, and the project is currently in the approval process. While continuously optimizing the layout and expanding the R&D and manufacturing capacity, the R&D system with independent intellectual property rights and efficient R&D capabilities was developed, and will be officially put into use in the first half of 2022.

Mr. Jia Di said, as one of the outstanding enterprise representatives in Huaming Hi-tech Zone, Laviana Pharma has become a leading CDMO serving new drug development and production with its innovation endeavors and unremitting efforts, and has played a good role as a model. Leaders at all levels and relevant departments of the district attach great importance to the development of Tianjin Laviana. The district government will always keep an eye on Laviana's progress, proactively create a superior, healthy, innovative entrepreneurial environment for Laviana. Priorities will be given to key fields, such as complete the approval process as soon as possible in the case of compliance with various reporting and approval requirements, making the project landed sooner to help the enterprise create more value.

Under the policy guidance and care of leaders at all levels in the district, Tianjin Laviana will continue to follow the path of innovative development, play a leading role as a high-quality enterprise, focus on improving the comprehensive strength of R&D and production, boost the pace of innovative drug listing and create a brighter future for medical and health industry!